OncoMatch/Clinical Trials/NCT06325501
Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy
Is NCT06325501 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Misoprostol 200mcg Tab and Oxytocin for myoma;uterus.
Treatment: Misoprostol 200mcg Tab · Oxytocin — Uterine leiomyomas, or fibroids, are common benign tumors among women, especially those over 35 years old. They can cause various issues, including heavy menstrual bleeding, anemia, pelvic pain, and pressure symptoms. Surgery is often necessary for symptomatic fibroids, with hysterectomy recommended for women over 40 and myomectomy for those wishing to preserve their uterus. Myomectomy can be performed using different surgical approaches but can be associated with significant morbidity, particularly major blood loss, especially in abdominal myomectomy, where up to 20% of women may require blood transfusion. Various interventions have been introduced to reduce bleeding during myomectomy, such as tourniquets, bupivacaine plus epinephrine infiltration, vasopressin injection, preoperative GnRH agonist administration, and preoperative ascorbic acid injection. However, these strategies may have complications, be ineffective, expensive, or require extra steps. Oxytocin, primarily secreted from the pituitary gland, is crucial for uterine contraction during labor and delivery, and is used to prevent postpartum uterine atony and bleeding. However, caution is needed in its use, especially in women with heart disease or hypovolemia. Misoprostol, a prostaglandin E1 analogue, can reduce bleeding during myomectomy by promoting myometrial contractions and reducing uterine artery blood flow. It can be administered via multiple routes, with rectal administration showing advantages in maintaining high plasma concentrations during surgery. Studies have investigated the effectiveness of single preoperative rectal doses of misoprostol versus preoperative oxytocin in reducing bleeding during abdominal myomectomy.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IV, 5, 6 (FIGO)
Excluded: Stage 0, I, II, 7, 8
Intramyometrial myoma staging from (3 to 6) according to FIGO staging ... Intracavitary, submucosal, pedunculated Subserosal and adnexal Myoma FIGO staging 0,1,2,7,8.
Prior therapy
Cannot have received: myomectomy
History of previous myomectomy
Cannot have received: abdominal or pelvic operation for non-obstetric cause
history of any abdominal or pelvic operation for non-obstetric cause
Lab requirements
Blood counts
Anemia (Hb < 10g %) excluded; bleeding disorders excluded
Anemia (Hb < 10g %). Patients who have bleeding disorders. Cardiac and Pulmonary diseases. Renal and hepatic impairment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify